Optimal management of metastatic renal cell carcinoma: current status.
about
Serum and urine biomarkers for human renal cell carcinomaBrazilian data of renal cell carcinoma in a public university hospitalSunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckIdentification of a suitable qPCR reference gene in metastatic clear cell renal cell carcinoma.Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.Renal cell carcinoma with intramyocardial metastasesIL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Comparing comparators: a look at control arms in kidney cancer studies over the years.Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysisA case study on the potential angiogenic effect of human chorionic gonadotropin hormone in rapid progression and spontaneous regression of metastatic renal cell carcinoma during pregnancy and after surgical abortion.Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population.IL-8 induces the epithelial-mesenchymal transition of renal cell carcinoma cells through the activation of AKT signaling.Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.The role of metastasectomy in renal cell carcinoma.Bevacizumab: a review of its use in advanced cancer.Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.Renal Cancer in the Elderly.Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-κB pathway contributes to the metastasis of renal cell carcinoma.Role of protein phosphatases in genitourinary cancers.How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.Sunitinib does not impair natural killer cell function in patients with renal cell carcinoma.Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma.Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.Prognostic relevance of androgen receptor expression in renal cell carcinomas.Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors.Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents.Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis.Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological responseMiR-543 promotes cell proliferation and metastasis of renal cell carcinoma by targeting Dickkopf 1 through the Wnt/β-catenin signaling pathway
P2860
Q28084949-0439802F-911E-4C5C-BEEE-0FBB29442C81Q31089209-86C0A80C-9A52-4893-9F15-74936CFA3811Q33424769-F066D760-5F4E-4740-BE11-6FE42B52444DQ33650470-CBABE2E6-EFAF-403F-A006-52FB39BD815CQ34767097-0243EFFC-DDA9-4744-9891-5CA7651E05BFQ35152565-4EE58F34-AB86-4D36-9668-A6FEF280EF0AQ35240289-0331C9FD-EC50-4FBF-8CA4-7316D8F4BB11Q35274936-94D1A00C-6217-4B1B-82DF-EB34C8888943Q35677657-DA4A122D-2CBA-4FDC-8902-A98FB7F2CBA3Q35758408-5AADDCEA-E06B-4B89-B89B-0CD93B45F7C4Q35878497-517EF18C-3526-4CB7-90E8-DF067C091287Q35887319-FC6A96FA-C508-49F3-9890-C41EB3E1F921Q37013694-4F195783-57C9-41C8-9AA9-6F9797608A44Q37204389-3C60C1A8-594B-4C0B-8F4F-D6E678ECD29FQ37290050-E1AC3247-D081-41D3-A407-550E64F0C6E6Q37320131-895159E8-9F16-4FD5-9AC4-5600B791AD6EQ37536769-E78CE9C8-F641-4A5D-A30C-F89113D5AD45Q37702041-AE222533-6B49-4245-899D-EF999673095BQ38162921-74EA02F7-FF92-419B-AE74-37C6BBC823ADQ38260176-C78FC572-7B31-4B53-841F-0835C8470FA0Q38261099-51BE1BB5-DDE6-43BE-B0BD-16E7DA699FABQ38525475-C8AEBCC2-1D3A-4B9F-85A8-A768C29B71F4Q38647604-1AE72F0A-28A9-4850-8786-4FFA1B7EC933Q38682520-7255B333-8C23-4E8C-836E-CFC554632522Q38721253-4805C19D-09C7-497B-AF54-D36EFE0498C2Q38824994-3ADC939D-B384-4F68-8E2E-3DABAD11EE05Q38941676-11BD9F36-08FF-40D6-8B3B-A03ACEC22B96Q39065451-7F503C55-7D65-49D2-BC60-E01662949DF7Q40978726-CACE596D-3940-400B-AA99-F92684521830Q41505826-5B5787CA-6BA4-43C2-8899-7F872DC72EA7Q41573990-70454D08-04E3-4968-8501-E382A8064B6AQ42378358-B4B7A83E-FAF2-47F7-90E1-E141E6293AB3Q45519197-4A723D2B-18F1-41DE-9FA7-34FA7A6ABC57Q47131818-F2578528-91EF-4A98-9882-4BCC16CC0AA5Q48067491-778EA03F-7E8A-4EFB-8DB9-3DE6E3E64343Q52906446-26E8A8EA-5C2A-4D1D-83A1-F58573712F75Q53634559-770B2B32-F863-49D6-B078-BA90E3B1E446Q55061628-879DBC35-6B00-458E-A40B-3AEFAC3B3D0EQ57578654-EA0EBEF5-4757-49CC-8152-D1DC73B7EE58Q58555659-F907CA7B-6597-4821-9DC9-372C3703C633
P2860
Optimal management of metastatic renal cell carcinoma: current status.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimal management of metastatic renal cell carcinoma: current status.
@en
type
label
Optimal management of metastatic renal cell carcinoma: current status.
@en
prefLabel
Optimal management of metastatic renal cell carcinoma: current status.
@en
P2860
P1433
P1476
Optimal management of metastatic renal cell carcinoma: current status.
@en
P2093
Guru Sonpavde
Laurence Albiges
P2860
P2888
P304
P356
10.1007/S40265-013-0043-1
P577
2013-04-01T00:00:00Z
P6179
1051875499